Navigation Links
Innovive Pharmaceuticals to Present Interim Data from Phase I Study,of INNO-406 at the American Society of Clinical Oncology Annual,Meeting

NEW YORK--(BUSINESS WIRE)--May 30, 2007 - INNOVIVE Pharmaceuticals, Inc. (OTCBB: IVPH) today announced that interim data from a Phase I trial of INNO-406, an orally bioavailable dual Bcr-Abl and Lyn-kinase inhibitor for Gleevec(R)-resistant or treatment-intolerant chronic myelogenous leukemia, will be presented at the 43rd American Society of Clinical Oncology Annual Meeting. The meeting takes place June 1- 5, 2007 at McCormick Place in Chicago, Illinois.

Information related to the presentation is as follows: -0-

Presentation Title: "A phase I study of INNO-406, a dual inhibitor of

                    Abl and Lyn kinases, in adult patients with

                    Philadelphia chromosome positive (Ph+) chronic

                    myelogenous leukemia (CML) or acute lymphocytic

                    leukemia (ALL) relapsed, refractory, or intolerant

                    of imatinib"

Abstract Number:    7046

Session:            General Poster Session, Leukemia, Myelodysplasia

                    and Transplantation, Poster Board #L2

Location:           S Hall A2, McCormick Place

Session Date:       Saturday, June 2, 2007

Session Time:       8:00 a.m. - 12:00 p.m.

About INNO-406

INNO-406 (formerly known as NS-187) is a potent, oral, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor currently being investigated in a Phase I clinical study. According to a study published in the journal Blood (Dec. 1, 2005), INNO-406 is 25- to 55-times more potent than imatinib in vitro and is at least 10-times as effective as imatinib mesylate in suppressing the growth of Bcr-Abl bearing tumors. INNO-406 has demonstrated activity in 18 of 19 imatinib-resistant cell lines. In addition to its Bcr-Abl inhibitory properties, INNO-406 inhibits Lyn kinase. Upregulation of Lyn kinase activity is a well recognized cause of imatinib resistance. Lyn kinase activation has also been documented in a v ariety of solid tumors, including prostate cancer.

About INNOVIVE Pharmaceuticals

INNOVIVE Pharmaceuticals, Inc. acquires, develops and commercializes novel therapeutics addressing significant unmet medical needs in the fields of oncology and hematology. The company has four drug programs in clinical development: INNO-406, Tamibarotene, INNO-206, and INNO-305, for the treatment of chronic myelogenous leukemia, acute promyelocytic leukemia, small cell lung cancer, and acute myelogenous leukemia, respectively. For additional information visit www.innovivepharma.com.

Gleevec(R) is a registered trademark of Novartis Pharmaceuticals Corporation.

Contact

INNOVIVE Pharmaceuticals, Inc.
Steve Kelly, President and CEO, 212-716-1820
or
Media & Investor Relations:
Porter Novelli Life Sciences
Rachel Lipsitz, 619-849-5378


'"/>




Related medicine technology :

1. Innovive Pharmaceuticals Announces Preclinical Data from INNO-206 Oncology Program
2. Innovive Pharmaceuticals Announces Additional Data Presentations at American Association for Cancer Research Annual Meeting
3. Innovive Pharmaceuticals Announces Data from Oncology Drug Programs to be Presented at American Association for Cancer Research Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... , May 10, 2017  The Corporate Whistleblower ... employees of sleep therapy clinics to call us ... therapy clinic is involved in a substantial scheme ... in hearing from an employee of a medical ... a kickback scheme to provide medical practice groups with ...
(Date:5/9/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... has earned a spot on Forbes, "America,s ... ranked among 500 U.S. employers as well as in ... Services. The annual Forbes rankings ... of over 30,000 employees across 25 industries. The survey ...
(Date:5/9/2017)... Ore. , May 9, 2017  Semler ... that provides technology solutions to improve the clinical ... financial results for the first quarter ended March ... our products enable our customers to identify when ... to intervene before events like heart attacks or ...
Breaking Medicine Technology:
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... ... recently completed Course II of the HP3 (High-Performance Periodontal Practice) continuing education (CE) ... learning the latest advancements in his field by attending numerous CE courses each ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... offering holistic pediatric dentistry options for its patients on Long Island, New York. ... entire physical well being, and is one of the biggest trends in dentistry ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dymedix® ... diagnostics sensors, announced today it had completed the first phase of building a ... domestic and rest of world (ROW) authorized dealers specializing in polysomnography accessories. ...
(Date:5/23/2017)... MA (PRWEB) , ... May 23, 2017 , ... ... claim in North Carolina have remained steady since 2009, according to a Workers ... era. , The study Monitoring the North Carolina System: CompScope™ Benchmarks, 17th ...
(Date:5/23/2017)... , ... May 23, 2017 , ... ... and Reconstructive Surgeon Dr. Kevin Sadati, is pleased to announce a new treatment ... collagen and elastin in their face, neck, and body through a virtually pain-free, ...
Breaking Medicine News(10 mins):